Huaan France CAC40 ETF(QDII)

Sanofi and Regeneron's Dupixent Reaches All Study Endpoints, Accepted by FDA for Priority Review

Berenberg Maintains Buy Rating on Sanofi with a Target Price of €110

Berenberg Bank Maintains Buy Rating on Sanofi

Sanofi, Caihui Fund, and Yanshipiao Sign Strategic Collaboration in Biopharmaceutical Innovation

Sanofi First Exhibits Dupixent for Chronic Rhinosinusitis with Nasal Polyps

Sanofi's Kavdiva Approved by China's National Medical Products Administration

Sanofi Raises $3 Billion Through Multi-Part Bond Issuance

Sanofi to Continue to Increase Layout and Investment in China

Sanofi Announces Positive Results from Phase II Clinical Study of Efdalivirsen for Alpha-1 Antitrypsin Deficiency Emphysema

Papadakis Maintains Buy Rating on Sanofi With a Price Target of 119 Euros

Sanofi Plans to Establish New French Headquarters in La Défense

Sanofi to showcase cardiovascular innovations at CIIE

Medidata Expands Collaboration with Sanofi to Enhance Clinical Trial Efficiency

Sanofi Prices $3 Billion Bond Offering

Medidata extends clinical research collaboration with Sanofi

Sanofi Submits Application for Floating Rate Notes Offering

Sanofi Announces 2025 First Half Financial Results

Leerink Partners Raises Sanofi Price Target to €98

Sanofi Reports 7.8% Drop in Quarterly Vaccine Sales

Sanofi Reports Quarterly Earnings Per Share Above Expectations

SNYNF

Sanofi, Regeneron's Dupixent Reduces Signs, Symptoms of Sinus Condition in Late-stage Trial

marketscreener

Sanofi

Sanofi, Regeneron's Dupixent Reduces Signs, Symptoms of Sinus Condition in Late-stage Trial

ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis. sBLA accepted for FDA priority review ...

GlobeNewswire

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Sanofi and Regeneron announced that the FDA has accepted their supplemental biologics license application for Dupixent in treating allergic fungal rhinosinusitis. This application is based on positive Phase 3 study results. The FDA's target action date is February 28, 2026. If approved, Dupixent will be the first medicine specifically indicated for this condition, marking its ninth FDA-approved indication.

Reuters

FDA Accepts Priority Review for Sanofi and Regeneron’s Dupixent in Allergic Fungal Rhinosinusitis

In a report released yesterday, from Berenberg Bank maintained a Buy rating on Sanofi, with a price target of $69.00. The company’s shares closed yesterday at $49.49.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. Currently, the analyst consensus on Sanofi is a Strong Buy with an average price target of $62.50.

Tip Ranks

Berenberg Bank Remains a Buy on Sanofi (SNY)

Berenberg Bank has maintained a Buy rating on Sanofi (SNYNF) with a price target of €110.00, while the shares closed at €85.61. Analyst Luisa Hector, a 4-star analyst, has an average return of 5.8% and a 64.52% success rate. The consensus on Sanofi is a Strong Buy with an average price target of $120.82, indicating a potential upside of 41.13%. Deutsche Bank also supports a Buy rating with the same price target of €110.00.

Berenberg Bank Remains a Buy on Sanofi (SNYNF)

The CNS Summit unveiled its annual Digital Innovation Index, developed with IDEA Pharma, during its meeting on November 4. The Index ranks biopharma companies on digital innovation across technology advancement, clinical trial optimization, and collaborative innovation. Roche retained the top position, reflecting consistent leadership in digital capabilities. Other top firms include AstraZeneca, Sanofi, Pfizer, and Bayer, focusing on strategic collaborations and global growth. The report highlights a significant shift in digital innovation, particularly with AI integration in research and clinical processes, marking a transformative year for the industry.

- The CNS Summit Digital Innovation Index, launched on November 4, evaluates biopharma companies' digital innovation in technology, clinical trials, and collaboration, with a focus on AI integration this year.  
- Roche maintained its top ranking, reflecting consistent digital capability, while other leading firms like AstraZeneca and Pfizer emphasized strategic collaborations and global growth.  
- Industry leaders noted a significant shift in digital innovation, highlighting the integration of generative AI and remote monitoring in clinical trials, which is transforming patient care delivery.

prnewswire

08:34 ET
			
			
				CNS Summit releases annual Digital Innovation Index

Corporate venture firms have become key players in funding biotech startups amid a slowdown in traditional funding. Notable firms like Novo Holdings, Eli Lilly, and Sanofi have significantly increased their investment activity, participating in 44 private funding rounds in 2025 compared to just 11 in 2022. These corporate investors provide a stable capital source, allowing for long-term strategies and enhancing the appeal of startups to other investors. Their involvement is seen as a validation of the science behind these companies, which is crucial during a challenging funding environment.

biopharmadive

Eli Lilly

Corporate venture firms stepped in for drug startups during biotech funding pullback

The chronic progressive multiple sclerosis market is projected to grow significantly from 2025 to 2034, driven by rising prevalence, increased disease awareness, and the launch of new therapies like BTK inhibitors. DelveInsight's report highlights the anticipated market expansion in major regions, particularly the US, with approximately 1.6 million cases expected in 2024. Key players such as Sanofi and Roche are developing promising therapies, including Tolebrutinib, which has shown potential in slowing disease progression. The market is evolving with ongoing clinical trials and a shift towards personalized treatment approaches.

17:31 ET
			
			
				Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion During the Forecast Period (2025-2034) Due to Strong Pipeline and Advanced Therapeutic Strategies | DelveInsight